The economic evaluation of personalised oncology medicines: ethical challenges
| Autor: | Jan R.R. Lewis, Ian Kerridge, Richard O. Day, Wendy Lipworth |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Advisory committee Cost-Benefit Analysis Antineoplastic Agents Erlotinib Hydrochloride Gefitinib Internal medicine Carcinoma Non-Small-Cell Lung Neoplasms Medicine Humans Precision Medicine Randomized Controlled Trials as Topic Cost–benefit analysis business.industry Australia Cancer General Medicine Precision medicine medicine.disease ErbB Receptors Treatment Outcome Economic evaluation Cancer management Quinazolines Erlotinib business medicine.drug |
| Zdroj: | The Medical journal of Australia. 199(7) |
| ISSN: | 1326-5377 |
| Popis: | Insights into the molecular drivers of cancer are providing opportunities for the development of new targeted treatments and more personalised approaches to cancer management. Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). First-line access to these newer treatments remains unfunded after several considerations by the Pharmaceutical Benefits Advisory Committee and their assessment that these are not cost-effective treatments. We suggest that there may be evidentiary and ethical challenges associated with the assessment of the cost-effectiveness of personalised oncology medicines in Australia, and that a new approach is needed to determine the value and cost-effectiveness of personalised medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text